FDA Signs Off on Phase 3 Trial Design for Enliven's Relcobatinib in CML
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (2.1× avg).
Summary
Enliven Therapeutics and the FDA have reached agreement on the phase 3 trial design for relcobatinib in chronic myeloid leukemia. This is a key regulatory milestone that de-risks the pivotal program and sets the path toward a potential registration study. The company's lead candidate now has a clear late-stage development plan, which could accelerate timelines and attract partnership interest. No specific trial start date or patient enrollment figures were disclosed in the headline. The news follows a period of routine insider selling under pre-arranged 10b5-1 plans, which does not alter the fundamental outlook.
At the time of this announcement, ELVN was trading at $42.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $14.79 to $62.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.